Bevacizumab in advanced lung cancer: state of the art
Bevacizumab in advanced lung cancer: state of the art
About this item
Full title
Author / Creator
Publisher
England: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Despite recent advances in metastatic lung cancer treatment with the advent of immune checkpoint inhibitors and molecules targeting addictive genomic abnormalities, prognosis of most of the patients remains unfavorable. Combination approaches with older drugs, such as bevacizumab, should be thus envisioned. Bevacizumab is a monoclonal anti-VEGF ant...
Alternative Titles
Full title
Bevacizumab in advanced lung cancer: state of the art
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1929897939
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1929897939
Other Identifiers
ISSN
1479-6694,1744-8301
E-ISSN
1744-8301
DOI
10.2217/fon-2017-0302
